Fujirebio Diagnostics, Inc. Email Format

Biotechnology ResearchPennsylvania, United States201-500 Employees

Fujirebio Diagnostics, Inc. operates in biotechnology research with a focus on in vitro diagnostics, developing tests and biomarkers that support clinical decision-making. Its IVD offerings span manual to automated testing, delivering diagnostic results that hold clinical value across disease areas. The company collaborates with clinicians and industry partners to bring diagnostic markers to global markets through a broad distribution network spanning the United States, Latin America, Europe and Asia.

Founded in 1950 in Tokyo, Japan, the company is now headquartered in Malvern, Pennsylvania, and functions as a consolidated subsidiary of H.U. Group Holdings. Recent developments include strategic collaborations, such as with Stanford Medicine in 2025, and the 2026 launch and CE marking of the lumipulse G NfL Blood assay.

Sign up for free to view info

Company overview Employee directory